{"success":true,"data":{"pressRelease":{"id":"167271","rtpr_id":"nPnbLT4pPa-20261013","ticker":"SCNI","exchange":"NASDAQ","all_tickers":["SCNI","2F50Y"],"title":"Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement","author":"PR Newswire","published_at":"2026-10-13T11:00:08.287Z","article_body":"Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement\nPR Newswire\n\nJERUSALEM, Oct. 13, 2026\n\nCommitted Customer Orders¹ reach approximately $7.6 million, up approximately\n300% from $1.9 million at year-end 2025\n\nAgreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports\ndevelopment activity in 2026 and clinical manufacturing planned for 2027\n\nPotential additional clinical manufacturing carries an indicative, uncommitted\nservice-fee value of $5.85 million for late 2027 through the first half of\n2028, excluding additional scale-up, qualification and initial manufacturing\nactivities not yet priced\n\nJERUSALEM, Oct. 13, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.\n(https://www.scinai.com/) (Nasdaq: SCNI) (\"Scinai\" or the \"Company\"), a\nbiopharmaceutical company operating a growing contract development and\nmanufacturing organization (\"CDMO\") alongside an immunology-focused\ntherapeutic development platform, today announced that its wholly owned\nsubsidiary, Scinai Biopharma Services Ltd. (https://www.scinai.com/cdmo) , has\nentered into a definitive development and clinical manufacturing agreement\nwith a U.S.-based, Nasdaq-listed biopharmaceutical company.\n\nThe agreement expands a previously disclosed customer engagement and includes\napproximately $5.1 million in committed base service fees, subject to\nperformance and the agreement's terms, including applicable termination\nrights. The services are expected to contribute to revenue during 2026 and\n2027 as the relevant performance obligations are satisfied, with stability\nservices continuing beyond 2027. Advance and milestone payments for the\ncommitted services are expected to support cash flow and working capital\nduring project execution.\n\nFollowing execution, Scinai's Committed Customer Orders¹ across its Jerusalem\nand Yavne operations reached approximately $7.6 million, an increase of\napproximately 300% from $1.9 million at year-end 2025 and more than double the\napproximately $3.1 million reported as of August 16, 2026. The total excludes\nfuture pass-through purchases and associated markups until ordered and\ncommitted, as well as the potential additional manufacturing activities\ndescribed below.\n\nAmir Reichman, Chief Executive Officer of Scinai, commented:\n\n\"This agreement materially expands our contracted CDMO business and supports\nour strategy of delivering high-quality, bespoke CDMO services to\ninternational customers. It provides greater visibility into our manufacturing\nworkload for 2027 and combines development and IND-enabling activities\nunderway in 2026 with a clinical manufacturing program planned to begin in\nJanuary 2027.\"\n\n\"Our priority is to translate these commitments into revenue, increased\nfacility utilization and stronger operating performance, while continuing to\naggressively grow the business. The potential for additional clinical supply\nand, ultimately, commercial manufacturing illustrates how these customer\nrelationships can develop over time.\"\n\nCommitted services and project funding\n\nThe engagement covers integrated chemistry, manufacturing and controls (\"CMC\")\ndevelopment and clinical manufacturing for an investigational oncology\nproduct. Services include process and analytical development, manufacturing\nreadiness, IND-enabling activities, a clinical manufacturing program,\nstability testing and development of a prefilled-syringe presentation.\n\nPotential expansion during 2027 and 2028\n\nPotential additional clinical manufacturing has a combined indicative,\nuncommitted service-fee value of $5.85 million, with activities contemplated\nfor late 2027 through the first half of 2028.\n\nThese activities remain subject to agreement on final scope and pricing,\nwritten authorization, available manufacturing capacity, and the customer's\ndevelopment and regulatory progress. The indicative value excludes scale-up,\nmanufacturing-suite transition and qualification, and the first clinical batch\nin the new configuration, for which pricing has not yet been established. It\nalso excludes project-related costs. These potential activities are not\nincluded in the initial $5.1 million commitment or in Committed Customer\nOrders.\n\nThe relationship also creates an opportunity for future commercial\nmanufacturing, subject to the customer's clinical and regulatory progress,\nmanufacturing requirements and a separate commercial agreement. No commercial\nsupply volumes or related revenues are currently committed.\n\nAdditional project-related charges\n\nIn addition to the $5.1 million service commitment, Scinai will bill approved\nproject-related costs separately, including a procurement and handling charge\nwhere applicable. These charges are expected to generate additional revenue,\nalthough the amount recognized as revenue may differ from total customer\nbillings under applicable accounting requirements.\n\nAbout Scinai Immunotherapeutics\n\nScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company\noperating a growing contract development and manufacturing organization\nalongside an immunology-focused therapeutic development platform.\n\nThrough its wholly owned subsidiary, Scinai Biopharma Services Ltd., the\nCompany provides development and manufacturing services to biotechnology and\npharmaceutical companies at its facilities in Jerusalem and Yavne, Israel.\nScinai also advances its NanoAb platform through research collaboration and\nlicense arrangements with the Max Planck Society and University Medical Center\nGöttingen, both in Germany.\n\nFor more information, please visit www.scinai.com (https://www.scinai.com/) .\n\nCompany Contacts\n\nBusiness Development | +972 8 930 2529 | bd@scinai.com (mailto:bd@scinai.com)\nInvestor Relations, Allele Capital Partners | Brian DeBeer | +1 (561) 388-8178\n| Brian.DeBeer@scinai.com (mailto:Brian.DeBeer@scinai.com)\n\n¹ Committed Customer Orders\n\nCommitted Customer Orders represent the aggregate value of committed customer\norders for CDMO services and ordered project-specific pass-through charges,\nincluding applicable procurement and handling markups. The measure includes\norders carried forward from prior year and new orders received during the\nreporting year, including orders scheduled for fulfillment in the subsequent\nyear. Amounts invoiced or recognized as revenue during the reporting year\nremain included. Future pass-through purchases and associated markups are\nexcluded until ordered and committed; uncommitted service activities are also\nexcluded.\n\nManagement uses this supplemental operating measure to monitor\ncustomer-authorized activity and the scale of its contracted CDMO business. It\nis not calculated under GAAP, does not represent recognized revenue or\nremaining unfulfilled backlog, and does not guarantee future revenue or cash\nreceipts. It may not be comparable to similarly titled measures used by other\ncompanies. Revenue recognition and payment timing depend on service\nperformance, contractual milestones and applicable accounting requirements.\nProjects may be delayed or modified, and contractual termination provisions\nmay apply.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements under applicable U.S.\nsecurities laws, including the Private Securities Litigation Reform Act of\n1995. These statements address the expected scope, timing and financial\ncontribution of the customer engagement; anticipated revenue and cash receipts\nduring 2026, 2027 and subsequent periods; Committed Customer Orders;\ndevelopment and manufacturing schedules; potential additional clinical and\ncommercial manufacturing; facility utilization; and growth of Scinai's CDMO\nbusiness.\n\nActual outcomes may differ materially from current expectations. Relevant\nrisks include technical, analytical, manufacturing, quality or regulatory\ndifficulties; delays in equipment, materials or third-party services which can\nlead to delays in payments; changes in customer requirements or development\nplans; contractual modification or termination; delayed payments; failure to\nmeet milestones; failure to activate optional activities; and differences\nbetween anticipated billings, cash collections and recognized revenue.\nAdditional risks include financing requirements, competition, geopolitical\nconditions and the other risks described in the Company's Annual Report on\nForm 20-F and subsequent filings with the U.S. Securities and Exchange\nCommission.\n\nThe approximately $5.1 million service commitment remains subject to\nperformance and the agreement's terms, including applicable termination\nrights. Potential additional program values are indicative, uncommitted and\nsubject to final quotation and written authorization. No assurance is given\nthat these activities or commercial manufacturing will proceed.\n\nForward-looking statements reflect expectations as of the date of this\nrelease. Scinai undertakes no obligation to update them except as required by\nlaw.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/scinai-expands-cdmo-business-with-5-1-million-development-and-clinical-manufacturing-agreement-302906942.html\n(https://www.prnewswire.com/news-releases/scinai-expands-cdmo-business-with-5-1-million-development-and-clinical-manufacturing-agreement-302906942.html)\n\nSOURCE Scinai Immunotherapeutics Ltd.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS2012090/Scinai-Immunotherapeutics.jpg?id=OA3015156\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbLT4pPa-20261013","title":"Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement","author":"PR Newswire","ticker":"SCNI","created":"2026-10-13T11:00:08.287Z","tickers":["SCNI","2F50Y"],"exchange":"NASDAQ","article_body":"Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement\nPR Newswire\n\nJERUSALEM, Oct. 13, 2026\n\nCommitted Customer Orders¹ reach approximately $7.6 million, up approximately\n300% from $1.9 million at year-end 2025\n\nAgreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports\ndevelopment activity in 2026 and clinical manufacturing planned for 2027\n\nPotential additional clinical manufacturing carries an indicative, uncommitted\nservice-fee value of $5.85 million for late 2027 through the first half of\n2028, excluding additional scale-up, qualification and initial manufacturing\nactivities not yet priced\n\nJERUSALEM, Oct. 13, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.\n(https://www.scinai.com/) (Nasdaq: SCNI) (\"Scinai\" or the \"Company\"), a\nbiopharmaceutical company operating a growing contract development and\nmanufacturing organization (\"CDMO\") alongside an immunology-focused\ntherapeutic development platform, today announced that its wholly owned\nsubsidiary, Scinai Biopharma Services Ltd. (https://www.scinai.com/cdmo) , has\nentered into a definitive development and clinical manufacturing agreement\nwith a U.S.-based, Nasdaq-listed biopharmaceutical company.\n\nThe agreement expands a previously disclosed customer engagement and includes\napproximately $5.1 million in committed base service fees, subject to\nperformance and the agreement's terms, including applicable termination\nrights. The services are expected to contribute to revenue during 2026 and\n2027 as the relevant performance obligations are satisfied, with stability\nservices continuing beyond 2027. Advance and milestone payments for the\ncommitted services are expected to support cash flow and working capital\nduring project execution.\n\nFollowing execution, Scinai's Committed Customer Orders¹ across its Jerusalem\nand Yavne operations reached approximately $7.6 million, an increase of\napproximately 300% from $1.9 million at year-end 2025 and more than double the\napproximately $3.1 million reported as of August 16, 2026. The total excludes\nfuture pass-through purchases and associated markups until ordered and\ncommitted, as well as the potential additional manufacturing activities\ndescribed below.\n\nAmir Reichman, Chief Executive Officer of Scinai, commented:\n\n\"This agreement materially expands our contracted CDMO business and supports\nour strategy of delivering high-quality, bespoke CDMO services to\ninternational customers. It provides greater visibility into our manufacturing\nworkload for 2027 and combines development and IND-enabling activities\nunderway in 2026 with a clinical manufacturing program planned to begin in\nJanuary 2027.\"\n\n\"Our priority is to translate these commitments into revenue, increased\nfacility utilization and stronger operating performance, while continuing to\naggressively grow the business. The potential for additional clinical supply\nand, ultimately, commercial manufacturing illustrates how these customer\nrelationships can develop over time.\"\n\nCommitted services and project funding\n\nThe engagement covers integrated chemistry, manufacturing and controls (\"CMC\")\ndevelopment and clinical manufacturing for an investigational oncology\nproduct. Services include process and analytical development, manufacturing\nreadiness, IND-enabling activities, a clinical manufacturing program,\nstability testing and development of a prefilled-syringe presentation.\n\nPotential expansion during 2027 and 2028\n\nPotential additional clinical manufacturing has a combined indicative,\nuncommitted service-fee value of $5.85 million, with activities contemplated\nfor late 2027 through the first half of 2028.\n\nThese activities remain subject to agreement on final scope and pricing,\nwritten authorization, available manufacturing capacity, and the customer's\ndevelopment and regulatory progress. The indicative value excludes scale-up,\nmanufacturing-suite transition and qualification, and the first clinical batch\nin the new configuration, for which pricing has not yet been established. It\nalso excludes project-related costs. These potential activities are not\nincluded in the initial $5.1 million commitment or in Committed Customer\nOrders.\n\nThe relationship also creates an opportunity for future commercial\nmanufacturing, subject to the customer's clinical and regulatory progress,\nmanufacturing requirements and a separate commercial agreement. No commercial\nsupply volumes or related revenues are currently committed.\n\nAdditional project-related charges\n\nIn addition to the $5.1 million service commitment, Scinai will bill approved\nproject-related costs separately, including a procurement and handling charge\nwhere applicable. These charges are expected to generate additional revenue,\nalthough the amount recognized as revenue may differ from total customer\nbillings under applicable accounting requirements.\n\nAbout Scinai Immunotherapeutics\n\nScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company\noperating a growing contract development and manufacturing organization\nalongside an immunology-focused therapeutic development platform.\n\nThrough its wholly owned subsidiary, Scinai Biopharma Services Ltd., the\nCompany provides development and manufacturing services to biotechnology and\npharmaceutical companies at its facilities in Jerusalem and Yavne, Israel.\nScinai also advances its NanoAb platform through research collaboration and\nlicense arrangements with the Max Planck Society and University Medical Center\nGöttingen, both in Germany.\n\nFor more information, please visit www.scinai.com (https://www.scinai.com/) .\n\nCompany Contacts\n\nBusiness Development | +972 8 930 2529 | bd@scinai.com (mailto:bd@scinai.com)\nInvestor Relations, Allele Capital Partners | Brian DeBeer | +1 (561) 388-8178\n| Brian.DeBeer@scinai.com (mailto:Brian.DeBeer@scinai.com)\n\n¹ Committed Customer Orders\n\nCommitted Customer Orders represent the aggregate value of committed customer\norders for CDMO services and ordered project-specific pass-through charges,\nincluding applicable procurement and handling markups. The measure includes\norders carried forward from prior year and new orders received during the\nreporting year, including orders scheduled for fulfillment in the subsequent\nyear. Amounts invoiced or recognized as revenue during the reporting year\nremain included. Future pass-through purchases and associated markups are\nexcluded until ordered and committed; uncommitted service activities are also\nexcluded.\n\nManagement uses this supplemental operating measure to monitor\ncustomer-authorized activity and the scale of its contracted CDMO business. It\nis not calculated under GAAP, does not represent recognized revenue or\nremaining unfulfilled backlog, and does not guarantee future revenue or cash\nreceipts. It may not be comparable to similarly titled measures used by other\ncompanies. Revenue recognition and payment timing depend on service\nperformance, contractual milestones and applicable accounting requirements.\nProjects may be delayed or modified, and contractual termination provisions\nmay apply.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements under applicable U.S.\nsecurities laws, including the Private Securities Litigation Reform Act of\n1995. These statements address the expected scope, timing and financial\ncontribution of the customer engagement; anticipated revenue and cash receipts\nduring 2026, 2027 and subsequent periods; Committed Customer Orders;\ndevelopment and manufacturing schedules; potential additional clinical and\ncommercial manufacturing; facility utilization; and growth of Scinai's CDMO\nbusiness.\n\nActual outcomes may differ materially from current expectations. Relevant\nrisks include technical, analytical, manufacturing, quality or regulatory\ndifficulties; delays in equipment, materials or third-party services which can\nlead to delays in payments; changes in customer requirements or development\nplans; contractual modification or termination; delayed payments; failure to\nmeet milestones; failure to activate optional activities; and differences\nbetween anticipated billings, cash collections and recognized revenue.\nAdditional risks include financing requirements, competition, geopolitical\nconditions and the other risks described in the Company's Annual Report on\nForm 20-F and subsequent filings with the U.S. Securities and Exchange\nCommission.\n\nThe approximately $5.1 million service commitment remains subject to\nperformance and the agreement's terms, including applicable termination\nrights. Potential additional program values are indicative, uncommitted and\nsubject to final quotation and written authorization. No assurance is given\nthat these activities or commercial manufacturing will proceed.\n\nForward-looking statements reflect expectations as of the date of this\nrelease. Scinai undertakes no obligation to update them except as required by\nlaw.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/scinai-expands-cdmo-business-with-5-1-million-development-and-clinical-manufacturing-agreement-302906942.html\n(https://www.prnewswire.com/news-releases/scinai-expands-cdmo-business-with-5-1-million-development-and-clinical-manufacturing-agreement-302906942.html)\n\nSOURCE Scinai Immunotherapeutics Ltd.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS2012090/Scinai-Immunotherapeutics.jpg?id=OA3015156\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T11:00:08.353642159Z","server_sent_at_ms":1791889208353},"received_at":"2026-10-13T11:00:08.404Z","source_url":"https://www.prnewswire.com/news-releases/scinai-expands-cdmo-business-with-5-1-million-development-and-clinical-manufacturing-agreement-302906942.html"},"analysis":{"id":"155583","press_release_id":"167271","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Committed orders are subject to contractual termination rights and performance terms","$5.85M expansion value is indicative and uncommitted; commercial supply unpriced and uncommitted","Committed Customer Orders is a non-GAAP supplemental measure, not recognized revenue or backlog"],"eventType":"operations_update","narrative":"Scinai's CDMO subsidiary signed a definitive $5.1 million development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company covering CMC development and clinical manufacturing for an investigational oncology product.\n\nFollowing the signing, Committed Customer Orders reached approximately $7.6 million, up roughly 300% from $1.9 million at year-end 2025, with services contributing to revenue across 2026 and 2027.\n\nAn additional $5.85 million of potential clinical manufacturing for late 2027 through mid-2028 remains uncommitted, and future commercial manufacturing would require a separate agreement.\n\nThe deal improves 2027 workload visibility and cash flow via advance and milestone payments, though amounts remain subject to termination rights and performance terms.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Committed CDMO order book quadruples to $7.6M on a $5.1M oncology contract -- early revenue traction for Scinai's services pivot."},"keyFigures":{"dealValueUsd":5100000,"customDimensions":{"committed_customer_orders":"$7.6 million (up ~300% from $1.9 million at year-end 2025)","potential_uncommitted_fees":"$5.85 million (late 2027 through H1 2028)"}},"quotedText":"This agreement materially expands our contracted CDMO business and supports our strategy of delivering high-quality, bespoke CDMO services to international customers.","namedEntities":{"people":[{"name":"Amir Reichman","role":"CEO"},{"name":"Brian DeBeer","role":"Investor Relations, Allele Capital Partners"}],"products":["NanoAb platform"],"companies":[{"name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","relationship":"filer"},{"name":"Scinai Biopharma Services Ltd.","relationship":"subsidiary"},{"name":"Allele Capital Partners","relationship":"investor relations firm"},{"name":"Max Planck Society","relationship":"research collaborator"},{"name":"University Medical Center Göttingen","relationship":"research collaborator"}],"dollarAmounts":[{"amount":"$5.1 million","context":"committed base service fees under development and clinical manufacturing agreement"},{"amount":"$7.6 million","context":"Committed Customer Orders after execution"},{"amount":"$1.9 million","context":"Committed Customer Orders at year-end 2025"},{"amount":"$3.1 million","context":"Committed Customer Orders as of August 16, 2026"},{"amount":"$5.85 million","context":"indicative uncommitted service-fee value for potential additional clinical manufacturing"}]},"materialImpact":{"score":3,"reasoning":"A $5.1 million committed contract roughly quadruples the micro-cap CDMO's committed order book to ~$7.6 million with potential $5.85 million expansion, but amounts are small, subject to termination rights, and stretch over 2026-2028."},"tickerRelevance":{"others":[],"primary":"SCNI"},"globalImportance":22,"audienceRelevance":15,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"contract_win_small","dealSizeRelative":"material relative to small order book","householdBrandBoost":0}},"event_type":"operations_update","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":3,"narrative":"Scinai's CDMO subsidiary signed a definitive $5.1 million development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company covering CMC development and clinical manufacturing for an investigational oncology product.\n\nFollowing the signing, Committed Customer Orders reached approximately $7.6 million, up roughly 300% from $1.9 million at year-end 2025, with services contributing to revenue across 2026 and 2027.\n\nAn additional $5.85 million of potential clinical manufacturing for late 2027 through mid-2028 remains uncommitted, and future commercial manufacturing would require a separate agreement.\n\nThe deal improves 2027 workload visibility and cash flow via advance and milestone payments, though amounts remain subject to termination rights and performance terms.","key_figures":{"dealValueUsd":5100000,"customDimensions":{"committed_customer_orders":"$7.6 million (up ~300% from $1.9 million at year-end 2025)","potential_uncommitted_fees":"$5.85 million (late 2027 through H1 2028)"}},"named_entities":{"people":[{"name":"Amir Reichman","role":"CEO"},{"name":"Brian DeBeer","role":"Investor Relations, Allele Capital Partners"}],"products":["NanoAb platform"],"companies":[{"name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","relationship":"filer"},{"name":"Scinai Biopharma Services Ltd.","relationship":"subsidiary"},{"name":"Allele Capital Partners","relationship":"investor relations firm"},{"name":"Max Planck Society","relationship":"research collaborator"},{"name":"University Medical Center Göttingen","relationship":"research collaborator"}],"dollarAmounts":[{"amount":"$5.1 million","context":"committed base service fees under development and clinical manufacturing agreement"},{"amount":"$7.6 million","context":"Committed Customer Orders after execution"},{"amount":"$1.9 million","context":"Committed Customer Orders at year-end 2025"},{"amount":"$3.1 million","context":"Committed Customer Orders as of August 16, 2026"},{"amount":"$5.85 million","context":"indicative uncommitted service-fee value for potential additional clinical manufacturing"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T11:00:26.390Z","global_importance":22,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"contract_win_small","dealSizeRelative":"material relative to small order book","householdBrandBoost":0}},"durationMs":6921,"modelName":"glm-5.3-flashx"}}